Search

Position of EHA on Research Funding

 

The challenge
The cost of biomedical research is great, but the cost of disease is immense. An ageing population and expensive innovations in medicine put an increasing burden on already stressed healthcare budgets.

Read more

Position of EHA on Clinical Trials

 

The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.

Read more

Position of EHA on Personalized Medicine

 

The challenge
Despite its apparent complexity, personalized medicine could transform healthcare, by tailoring healthcare solutions to the individual patient, delivering ‘the right treatment to the right patient at the right time’ – and helping to get more value from healthcare spending.…

Read more

EHA supports the proposal for a Regulation on the European Health Data Space (EHDS)

On October 20, the European Hematology Association (EHA) joined a group of 35 stakeholders in welcoming the European Commission’s proposal on the European Health Data Space.

Read more

Jesus San Miguel presents the Ham-Wasserman Lecture at the 2014 ASH Annual Meeting

Professor San Miguel is a member of the Advisory board of the International Myeloma Foundation and the Multiple Myeloma Research Foundation.

Read more

EHA Statement of Solidarity with local communities in Türkiye and Syria

The European Hematology Association (EHA) is deeply concerned about the situation in southern Türkiye and northern Syria: Monday's earthquakes and aftershocks have killed thousands of people and destroyed innumerable buildings, while freezing temperatures and damaged roads are hampering rescue efforts.

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more